NCT03192033View on ClinicalTrials.gov

STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures

NACompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions
Peripheral Arterial Disease
Interventions
OTHER

Arterial closure to ensure hemostasis at femoral artery puncture points

Arterial closure devices used: Proglide® (Abbott)

DEVICE

Proglide® (Abbott)

Arterial closure device used: Proglide® (Abbott)

DEVICE

Femoseal® (Terumo)

Arterial closure device used: Femoseal® (Terumo)

OTHER

Arterial closure to ensure hemostasis at femoral artery puncture points

Arterial closure device used: Femoseal® (Terumo)

Trial Locations (6)

Unknown

CHU Angers, Angers

CHU Brest, Brest

CH de Cholet, Cholet

CHD La Roche-sur-Yon, La Roche-sur-Yon

CHU de Poitiers, Poitiers

CHU de Rennes, Rennes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT03192033 - STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures | Biotech Hunter | Biotech Hunter